https://www.pharmaceutical-technology.com/data-insights/si-101-sirpant-immunotherapeutics-mycosis-fungoides-likelihood-of-approval/
SI-101 is under clinical development by SIRPant Immunotherapeutics and currently in Phase I for Mycosis Fungoides.
mycosis fungoidesimmunotherapeuticslikelihood
https://stanfordhealthcare.org/trials/s/NCT00168064.html
Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more.
nitrogen mustardsafetyefficacytreatmentmycosis
https://stanfordhealthcare.org/trials/s/NCT00127881.html
Stanford Health Care delivers the highest levels of care and compassion. SHC treats cancer, heart disease, brain disorders, primary care issues, and many more.
human monoclonal antibodymycosis fungoidesstudytreat